Scholarlink

<p>The kinase family has emerged as a prime drug target; however, the complex network of interactions within this family considerably limits the efficacy of small-molecule kinase inhibitors. In this study, we developed a bispecific aptamer, termed as Met-Her, capable of inducing the degradation of multiple kinases, thereby weakening the interactions between them and triggering a cascade of biological effects, such as blocking downstream signaling pathways, inhibiting tumor cell migration and proliferation, and promoting apoptosis. In our <i>in vivo</i> studies, Met-Her demonstrated notable antitumor efficacy, which was further strengthened in combination with Capmatinib without any observable side effects. Overall, our strategy provides a novel perspective for receptor tyrosine kinase (RTK)-targeted therapeutics.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bispecific aptamers inhibit tumor growth by inducing degradation of multiple kinases

  • 期刊论文

  • 发表日期：

    2026年3月2日

查看全文
  • Shanchao Wu,
  • Tiantian Xie,
  • Yijun Yuan,
  • Yuping Yan,
  • Xinyi Zhou,
  • Yanxue Shang,
  • Aili Zhou,
  • Kun Chen,
  • Zilong Zhao,
  • Weihong Tan

摘要

The kinase family has emerged as a prime drug target; however, the complex network of interactions within this family considerably limits the efficacy of small-molecule kinase inhibitors. In this study, we developed a bispecific aptamer, termed as Met-Her, capable of inducing the degradation of multiple kinases, thereby weakening the interactions between them and triggering a cascade of biological effects, such as blocking downstream signaling pathways, inhibiting tumor cell migration and proliferation, and promoting apoptosis. In our in vivo studies, Met-Her demonstrated notable antitumor efficacy, which was further strengthened in combination with Capmatinib without any observable side effects. Overall, our strategy provides a novel perspective for receptor tyrosine kinase (RTK)-targeted therapeutics.